Aberdeen Group’s United Therapeutics UTHR Stock Holding History

Aberdeen Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Buy	517 +73	+16%	+$41.1K	﹤0.01%	919
2026 Q1	$263K	Buy	+444	New	+$221K	﹤0.01%	914
2024 Q3	–	Sell	-843	Closed	-$269K	–	969
2024 Q2	$269K	Sell	843 -27,369	-97%	-$7.24M	﹤0.01%	904
2024 Q1	$6.48M	Sell	28,212 -64	-0.2%	-$14.4K	0.01%	624
2023 Q4	$6.22M	Buy	+28,276	New	+$6.52M	0.01%	634
2019 Q2	–	Sell	-44,730	Closed	-$5.25M	–	938
2019 Q1	$5.25M	Hold	44,730	–	–	0.01%	622
2018 Q4	$4.71M	Sell	44,730 -24	-0.1%	-$2.78K	0.01%	577
2018 Q3	$5.72M	Buy	44,754 +16,039	+56%	+$1.98M	0.01%	598
2018 Q2	$3.25M	Sell	28,715 -5,068	-15%	-$557K	0.01%	663
2018 Q1	$3.8M	Sell	33,783 -36,865	-52%	-$4.68M	0.01%	591
2017 Q4	$10.5M	Sell	70,648 -786	-1%	-$99.9K	0.02%	447
2017 Q3	$8.37M	Buy	+71,434	New	+$9.12M	0.02%	478

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Aberdeen Group's UTHR Position: Q2 2026 in Review

Aberdeen Group increased its United Therapeutics (UTHR) stake by 16% in Q2 2026, buying an estimated $41.1K and bringing the position to 517 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Aberdeen Group first reported a position in UTHR in Q3 2017 and has held it in 12 quarters since. The position peaked at $10.5M in Q4 2017. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Aberdeen Group held 517 shares of United Therapeutics worth $280K as of Q2 2026.
Aberdeen Group bought 73 United Therapeutics shares in Q2 2026, an estimated $41.1K.
United Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #919 holding.
Aberdeen Group first reported a position in United Therapeutics in Q3 2017 and has held it in 12 quarters since.
Aberdeen Group's United Therapeutics position peaked at $10.5M in Q4 2017.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.